USP Adds New Layer Of Public Input On Part D Model Guidelines
Executive Summary
The U.S. Pharmacopeia is adding a new layer of public input into its first revision in three years to model guidelines for Medicare Part D formularies.
You may also be interested in...
USP Offers Few Changes In Part D Draft Model Formulary Guidelines For 2009
The U.S. Pharmacopeia's draft model formulary guidelines version 4.0 do not include additional therapeutic categories or pharmacologic classes compared with the current version
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.